LBA61 Durvalumab (durva) after sequential chemoradiotherapy (CRT) in patients (pts) with unresectable stage III NSCLC: Final analysis from PACIFIC-6
Garassino, M.C., Mazieres, J., Reck, M., Chouaid, C., Bischoff, H., Reinmuth, N., Cove-Smith, L.S., Mansy, T., Cortinovis, D.L., Migliorino, M.R., Delmonte, A., García Sanchez, J., Chara Velarde, L.E., Bernabe Caro, R., Paz-Ares, L., Chander, P., Diaz Perez, I., Foroutanpour, K., Faivre-Finn, C.
Published in Annals of oncology (01.10.2023)
Published in Annals of oncology (01.10.2023)
Get full text
Journal Article
108MO Safety and efficacy outcomes with durvalumab after sequential chemoradiotherapy (sCRT) in stage III, unresectable NSCLC (PACIFIC-6)
Garassino, M.C., Mazieres, J., Reck, M., Chouaid, C., Bischoff, H., Reinmuth, N., Cove-Smith, L., Mansy, T., Cortinovis, D., Migliorino, M.R., Delmonte, A., Garcia Sánchez, J., Chara Velarde, L.E., Bernabe, R., Paz-Ares, L., Diaz Perez, I., Trunova, N., Foroutanpour, K., Faivre-Finn, C.
Published in Annals of oncology (01.04.2022)
Published in Annals of oncology (01.04.2022)
Get full text
Journal Article